U.S. Markets
Novo Nordisk’s (NOVOB DC/NVO) Sogroya receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner syndrome
ORIGINAL · NewsquawkNovo Nordisk’s (NOVOB DC/NVO) Sogroya receives FDA approval as the first and only once-weekly, long-acting growth hormone for children with Turner syndrome
StockNow breaking-news AI analysis
The FDA approval makes Sogroya the first and only once-weekly, long-acting growth hormone for children with Turner syndrome.
Related stocks
1 stocksWhat do investors think?
Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactionsStockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.
